All In Biotech

NDA 020603 · Kenvue Brands

Children'S Motrin

Ibuprofen · Oral · Nonsteroidal Anti-inflammatory Drug

Last checked: Nov 20, 2026Latest source record: Mar 16, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Jun 10, 1996

Approved uses

2

Original approval plus efficacy supplements

Registered trials

910

162 Phase 3, 61 recruiting

FAERS reports

218,793

156,427 serious, 17,152 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 30, 2026.

Uses temporarily: reduces fever relieves minor aches and pains due to the common cold, flu, sore throat, headaches and toothaches

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 15, 1999 Supplement 3 · Efficacy Review
  • Jun 10, 1996 Original approval · Type 3 - New Dosage Form
1 products under this application
  • CHILDREN'S MOTRIN · IBUPROFEN 40MG/ML · SUSPENSION/DROPS, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Ibuprofen" as an intervention, any sponsor and status, largest first.

All 910 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective17,329
  • pain16,811
  • fatigue15,724
  • nausea15,160
  • headache13,607
  • arthralgia11,772
  • dyspnoea11,410
  • vomiting11,074
  • diarrhoea10,589
  • rash9,621
  • off label use9,430
  • dizziness9,213

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,980
20052,562
20062,553
20072,472
20082,181
20093,228
20104,737
20116,657
20128,227
20137,728
20147,342
201510,376
201613,937
201712,727
201816,879
201917,799
202016,353
202115,972
202215,260
202314,214
202413,151
202513,233
20269,215

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,679 on PubMed

Sponsor: Kenvue Brands

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.